top of page
Blog Posts
Search


The $10 billion unicorn in INmune Bio: cognition matters - on EMACC, CDR-SB, and why others may have failed
Summary Alzheimer’s is a disease of slowly fading cognition. If you would ask me how much my grandmother’s Alzheimer’s progressed over...
Carl Kestens
Apr 1115 min read
353 views
1 comment


The $10 billion unicorn in INmune Bio: on BioVie teachings and trustworthiness
Summary BioVie always argued that it saw a correlation between effects on cognition and reduction of TNF levels. That TNF reduction...
Carl Kestens
Mar 1410 min read
345 views
2 comments


The $10 billion unicorn in INmune Bio: Leqembi and Kisunla’s MoA is microglia-related, and amyloid beta is a cytokine
Introduction Amyloid beta has been the primary hallmark of Alzheimer’s disease for years. On the one hand, numerous trials focusing on...
Carl Kestens
Mar 615 min read
365 views
13 comments


The $10 billion unicorn in INmune Bio: where fraud and arrogance aren’t, solutions to AD are (C. Piller book coverage)
Introduction Science journalist Charles Piller wrote a book, called ‘Doctored: fraud, arrogance, and tragedy in the quest to cure...
Carl Kestens
Feb 2810 min read
363 views
1 comment


The $10 billion unicorn in INmune Bio: XPro’s biomarkers outperform Leqembi's and Kisunla's
Introduction For years, the scientific focus may have been too focused on targeting amyloid, while inflammation and modulation of glial...
Carl Kestens
Feb 215 min read
317 views
0 comments


The $10 billion unicorn in INmune Bio: inflammation drives cognitive decline
Summary INmune Bio is making significant strides across multiple programs, positioning itself as a major player in biotech. CORDstrom...
Carl Kestens
Feb 1311 min read
231 views
0 comments


The $10 billion unicorn in INmune Bio: On Cassava Sciences and the Importance of a Bear Thesis for Proper Due Diligence
Summary Coverage of the Alzheimer’s space would be incomplete without a blog post on Cassava Sciences. Now was the right time. Cassava...
Carl Kestens
Feb 711 min read
515 views
1 comment


The $10 billion unicorn in INmune Bio: Alzheimer’s, How Not To Study A Disease
On JLO, RFK, the NIH, TNF, Karl Herrup and innovation - a longer post. Â Summary The amyloid hypothesis did not yield the desired...
Carl Kestens
Jan 3113 min read
796 views
0 comments


The $10 billion dollar unicorn in INmune Bio: is the FDA openly suggesting accelerated approval based on NfL?
Summary I had a call with some investors earlier this week. During the call, the theme of accelerated approval came up. I had done a blog...
Carl Kestens
Jan 249 min read
522 views
0 comments


The $10 billion unicorn in INmune Bio: how only INMB uses the recipe behind big pharma’s recent successes with anti-amyloid antibodies
Historical failure rate of therapies targeting amyloid Alzheimer’s is characterized by aggregation of anti-amyloid antibodies and...
Carl Kestens
Jan 177 min read
685 views
0 comments


The $10 billion dollar unicorn in INmune Bio: could remyelination explain the fast functional/cognitive recovery seen in patients?
Introduction I am picking up my previous work to assess the Alzheimer’s space today, with a particular focus on INmune Bio, as the...
Carl Kestens
Jan 106 min read
1,019 views
0 comments


The $10 billion dollar unicorn in INmune Bio: on fast-progressors in AD, APOE4, TREM2 and EMACC
Summary APOE4, involved in different mechanisms in the brain including lipid homeostasis, is the strongest risk factor for Alzheimer’s...
Carl Kestens
Oct 21, 202212 min read
734 views
0 comments


The $10 Billion unicorn in INmune Bio: the potential of XPro in Parkinson’s
Summary The evolution of the treatment failures for Parkinson’s disease has striking similarities with Alzheimer’s. Just like in...
Carl Kestens
Sep 23, 202212 min read
625 views
0 comments


The FDA’s two leaps at once: on fast approval pathways and neurofilament light
Summary Neurofilament Light (NfL) is potentially the most important biomarker in neurodegenerative diseases. The FDA’s AdCom validated...
Carl Kestens
Sep 2, 20228 min read
633 views
0 comments


The $10 billion unicorn in INMB: on allostatic load, and why all the others may have non-responders
Summary Allostatic load is the cumulative burden of stressors one encounters throughout life. The underlying causes/triggers for any...
Carl Kestens
Jul 30, 20229 min read
756 views
1 comment


THE INFLAMED MIND, A Radical New Approach to Depression, by Ed Bullmore
A book review with some notes on my recent research, part I Introduction I have stated before that I believe that the field of psychiatry...
Carl Kestens
Jun 9, 20229 min read
136 views
0 comments


XPRO FOR THE DEPRESSED MIND, PART 1: INMB’S MOST IGNORED POTENTIAL
Introduction For some time now, INmune Bio has been announcing their trial in treatment resistant depression (TRD). The market, either...
Carl Kestens
May 7, 202213 min read
349 views
4 comments


THE $10 BILLION UNICORN IN INMUNE BIO: IT’S THE (MICRO)GLIA, STUPID!
Summary: · The detrimental action of glia, mostly microglia, in the inflamed brain is the last piece of the scientific puzzle; · ...
Carl Kestens
Apr 23, 202210 min read
674 views
7 comments


Medicare coverage refused for Aduhelm and amyloid-based therapies: what’s next?
The 7 April 2022 CMS decision denying Aduhelm medicare coverage On 7 April 2022, the Centers for Medicare and Medicaid Services (CMS)...
Carl Kestens
Apr 17, 20226 min read
145 views
0 comments


WHY IT IS SENSIBLE TO ADDRESS SUB-COHORTS IN ALZHEIMER’S DISEASE
"I think a good drug might fail in a clinical trial because not all the subjects have the same kind of Alzheimer's. Shubhabrata...
Carl Kestens
Apr 8, 20227 min read
398 views
1 comment
bottom of page